173 related articles for article (PubMed ID: 37433280)
1. Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy.
Kumagai S; Koyama S; Shitara K
Cancer Cell; 2023 Jul; 41(7):1199-1201. PubMed ID: 37433280
[TBL] [Abstract][Full Text] [Related]
2. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM; Chadwick JA; Owen RP; White MJ; Kaplinsky J; Peneva I; Frangou A; Xie PF; Chang J; Roth A; Amess B; James SA; Rei M; Fuchs HS; McCann KJ; Omiyale AO; Jacobs BA; Lord SR; Norris-Bulpitt S; Dobbie ST; Griffiths L; Ramirez KA; Ricciardi T; Macri MJ; Ryan A; Venhaus RR; Van den Eynde BJ; Karydis I; Schuster-Böckler B; Middleton MR; Lu X;
Cancer Cell; 2023 Jul; 41(7):1222-1241.e7. PubMed ID: 37433281
[TBL] [Abstract][Full Text] [Related]
3. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.
Zhang Z; Xie C; Gao T; Yang Y; Yang Y; Zhao L
BMC Cancer; 2023 Feb; 23(1):145. PubMed ID: 36765311
[TBL] [Abstract][Full Text] [Related]
4. Basis for molecular diagnostics and immunotherapy for esophageal cancer.
Abdo J; Agrawal DK; Mittal SK
Expert Rev Anticancer Ther; 2017 Jan; 17(1):33-45. PubMed ID: 27838937
[TBL] [Abstract][Full Text] [Related]
5. Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy.
Wang H; Xuan TT; Chen Y; Yu H; Gu TT; Zhou G; Liang L; Cao FL
Immunotherapy; 2020 Jul; 12(10):697-703. PubMed ID: 32580606
[No Abstract] [Full Text] [Related]
6. Are more courses of immunochemotherapy beneficial for the short-term outcome of locally advanced esophageal squamous cell carcinoma?
Huang Y; Su X; Guo Q; Luo G; He H; Cai P; Cai M; Yue H; Wang Z; Yang G; Lin P; Zhang X
Thorac Cancer; 2023 May; 14(13):1153-1161. PubMed ID: 36960736
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis.
Gao Z; Huang S; Wang S; Tang D; Xu W; Zeng R; Qiao G
Lancet Reg Health West Pac; 2023 Sep; 38():100841. PubMed ID: 37457900
[TBL] [Abstract][Full Text] [Related]
8. Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.
Cetin B; Wabl CA; Gumusay O
Immunotherapy; 2023 Aug; 15(12):945-962. PubMed ID: 37291863
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
Lu Y; Wang W; Wang F
Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
[TBL] [Abstract][Full Text] [Related]
10. Tsunami of immunotherapies in the management of esophageal cancer.
Kassab J; Saba L; Kassab R; Kourie HR
Immunotherapy; 2022 Aug; 14(11):879-884. PubMed ID: 35703028
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Bockorny B; Pectasides E
Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
[TBL] [Abstract][Full Text] [Related]
12. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis.
Zhang Y; Li C; Du K; Pengkhun N; Huang Z; Gong M; Li Y; Liu X; Li L; Wang D; Wang C; Chen F; Li J
Immunotherapy; 2023 Jul; 15(10):737-750. PubMed ID: 37139963
[TBL] [Abstract][Full Text] [Related]
15. The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.
Chen K; Wang X; Yang L; Chen Z
Cancer Control; 2021; 28():1073274821997430. PubMed ID: 33618535
[TBL] [Abstract][Full Text] [Related]
16. [Advances of immunotherapy-related biomarker in esophageal carcinoma].
Zhang RX; Kang XZ; Zheng QF; Wang Z; Chen XK; Li Y; Qin JJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Apr; 26(4):396-400. PubMed ID: 37072320
[TBL] [Abstract][Full Text] [Related]
17. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
18. How we treat esophageal squamous cell carcinoma.
Puhr HC; Prager GW; Ilhan-Mutlu A
ESMO Open; 2023 Feb; 8(1):100789. PubMed ID: 36791637
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer.
Yang J; Janjigian YY
Thorac Surg Clin; 2022 Nov; 32(4):467-478. PubMed ID: 36266034
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab as a first-line therapy in spinocellular esophageal cancer.
Křížová L; Charvát F; Petruželka L
Klin Onkol; 2021; 34(1):59-61. PubMed ID: 33657821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
